** Shares of Divi's Laboratories DIVI.NS up 3.7% to
3,788.75 rupees, steepest rise since December
** Pharma co reported ~17% rise in Q3 net profit, rev from
ops up ~9%
** Jefferies says it is bullish on the co, but expects
factors like improvement in pricing pressures for generics to
start unfolding only post FY26; cuts FY25E EPS by 3%
** Retains "hold" with unchanged PT of 3,610 rupees
** Brokerage PhillipCapital also flags ongoing margin
pressure in generics due to pricing pressures; cuts FY25 EPS by
14%, keeps rating at "neutral" with unchanged PT of 3,300 rupees
** Adds, co has potential to deliver surprise earnings
in upcoming quarters
** On avg, analysts' rating equivalent to "sell", their
median PT is 3,150 rupees - ~14% discount to its last close -
LSEG
** Co top gainer on Nifty Pharma index .NIPHARM , up 0.9%
** Trading volume is 1.3x 30-day avg
(Reporting by Manvi Pant in Bengaluru)
((Manvi.Pant@thomsonreuters.com; +918447554364;))